journal
MENU ▼
Read by QxMD icon Read
search

Drug and Therapeutics Bulletin

journal
https://www.readbyqxmd.com/read/28153847/spironolactone-potion-or-poison
#1
(no author information available yet)
No abstract text is available yet for this article.
February 2, 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28034861/dtb-select-1-january-2017
#2
(no author information available yet)
Brimonidine gel: risk of exacerbation of rosacea ● Metformin for patients with moderately reduced kidney function ● Effect of an optimal cranberry dose on bacteriuria ● Amitriptyline and topiramate ineffective for paediatric migraine prophylaxis ● Etoricoxib: 60mg dose for RA and ankylosing spondylitis ● CRP and diagnosis of CAP ● International travel and antimicrobial resistance ● Effect of telemedicine on diabetes control.
December 29, 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28183724/understanding-qualitative-research-in-health-care
#3
(no author information available yet)
Qualitative studies are often used to research phenomena that are difficult to quantify numerically.(1,2) These may include concepts, feelings, opinions, interpretations and meanings, or why people behave in a certain way. Although qualitative research is often described in opposition to quantitative research, the approaches are complementary, and many researchers use mixed methods in their projects, combining the strengths of both approaches.(2) Many comprehensive texts exist on qualitative research methodology including those with a focus on healthcare related research...
February 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28183723/%C3%A2-daclizumab-for-ms
#4
(no author information available yet)
▼Daclizumab (Zinbryta-Biogen Idec) is a new injectable disease-modifying drug licensed for the treatment of relapsing forms of multiple sclerosis (MS) in adults.(1) It is a humanised monoclonal antibody that modulates interleukin-2 signalling.(1-3) Here, we review the evidence on daclizumab and consider its place in the management of MS.
February 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28148539/dtb-select-2-february-2017
#5
(no author information available yet)
MHRA clarifies spironolactone advice ● Statin dosing: morning or evening? ● PPI use and risk of community-acquired pneumonia ● Non-inferiority trials: caution needed ● CV safety of celecoxib? ● ADRs and emergency department visits ● Study questions use of duloxetine in stress incontinence ● New oral anticoagulants: more on GI bleeding risk.
February 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28087755/%C3%A2-pitolisant-for-narcolepsy
#6
(no author information available yet)
▼Pitolisant (Wakix-Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.(1) Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.
January 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28087754/sore-throat-test-and-treat-a-%C3%A2-34-million-question
#7
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28057707/an-update-on-lama-laba-combinations-for-copd
#8
(no author information available yet)
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium,(1) ▼glycopyrronium,(2) tiotropium(3) and ▼umeclidinium,(4) and the long-acting beta2 agonists (LABAs) indacaterol,(5) ▼olodaterol,(6) and ▼vilanterol (in combination with fluticasone) in the management of COPD.(7) Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD...
January 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27979882/psychological-interventions-for-eating-disorders
#9
(no author information available yet)
Eating disorders, including anorexia nervosa, bulimia nervosa and binge eating disorder, are common conditions, characterised by disturbances of eating behaviours and a core psychopathology centred on food, eating and body image concerns.(1,2) Eating disorders are associated with medical and psychological comorbidities; a significantly impaired health-related quality of life; a high rate of inpatient, outpatient and emergency care; significant healthcare costs; and increased mortality.(3-10) Here, we focus on the evidence for non-drug interventions for eating disorders...
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27979881/an-update-on-the-gliptins
#10
(no author information available yet)
Progressive impairment of insulin secretion in people with type 2 diabetes leads to blood glucose concentrations worsening over time, often resulting in escalation of blood glucose lowering therapy.(1) In 2015/2016, more money was spent on dipeptidyl peptidase-4 (DPP-4) inhibitors ('gliptins') than on any other class of antidiabetic drug except for insulins.(2) In 2008, we reviewed sitagliptin and vildagliptin.(3) Here, we briefly review three other DPP-4 inhibitors, saxagliptin (Onglyza-AstraZeneca), linagliptin (Trajenta-Boehringer Ingelheim) and ▼alogliptin (Vipidia-Takeda), and consider data from recent cardiovascular outcomes studies...
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27979880/thank-you-to-contributors
#11
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27932384/wise-words
#12
(no author information available yet)
No abstract text is available yet for this article.
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27908909/dtb-select-12-december-2016
#13
(no author information available yet)
Azithromycin of no benefit for asthma attacks ● Risk of heart failure with NSAIDs ● Bisphosphonates and steroid-induced osteoporosis ● Triple therapy for moderate-to-severe COPD: marginal benefits ● Much data on adverse events remains unpublished ● Rising placebo response rates in antidepressant trials a 'myth' ● Prenatal fetal RhD testing recommended.
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27815301/a-history-of-rubella-immunisation
#14
(no author information available yet)
No abstract text is available yet for this article.
November 3, 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27799149/dtb-select-11-november-2016
#15
(no author information available yet)
Impact of hepatic enzyme-inducing drugs on levonorgestrel EHC ● New clinical rule to improve antibiotic prescribing to children ● The impact of nursery sickness policies on the treatment of conjunctivitis ● Patient safety alert for acute kidney injury ● Do strategies to reduce polypharmacy improve patient-relevant outcomes? ● When is a health app a medical device? ● Automated feedback reduces high-risk prescribing in primary care ● Quantifying resting heart rate as a predictor of disease.
October 31, 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27737908/point-of-care-crp-testing-in-the-diagnosis-of-pneumonia-in-adults
#16
(no author information available yet)
Respiratory tract infections (RTI) are among the most common acute conditions leading to GP consultations and to antibiotic prescribing in primary care, even though 70% are viral, and many others are minor self-limiting bacterial infections.(1-4) Between 0.5% and 1.1% of adults have community-acquired pneumonia every year in the UK, most of whom are managed in primary care.(4,5) The decision to prescribe antibiotics for an acute RTI in primary care is often based on clinical symptoms, which have low sensitivity and specificity, and high inter-observer variability...
October 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27737907/fosfomycin-for-utis
#17
(no author information available yet)
Fosfomycin trometamol is a broad spectrum antibiotic recently marketed in the UK for the treatment of acute uncomplicated lower urinary tract infections (UTIs) in adults(1,2) and in adult and adolescent females.(3) It is also indicated for prophylaxis in diagnostic and surgical transurethral procedures.(1-3) Fosfomycin was discovered in 1969 and the reference drug was first marketed as Monuril in France in 1986.(3,4) Although Monuril had UK marketing authorisation, it was never distributed in the UK. However, national guidance included the option of using unlicensed imported fosfomycin...
October 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27737906/21st-century-cure-19th-century-risk
#18
(no author information available yet)
No abstract text is available yet for this article.
October 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27694107/dtb-select-10-october-2016
#19
(no author information available yet)
Updated competency framework for all prescribers ● The risks of under-prescribing in older patients ● Self-monitoring and self-management of oral anticoagulation ● Role of sunscreen in preventing basal cell and squamous cell skin cancers ● Tech-based weight-loss intervention ● NICE guidance on NAFLD ● Modest improvement in sinus symptoms with nasal irrigation ● Exercise to offset the detrimental effects of sedentary habits.
October 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27609426/understanding-observational-studies
#20
(no author information available yet)
The development of evidence-based medicine has encouraged clinicians to consider the best available evidence when making clinical decisions, individualised for the patient.(1,2) A hierarchy of levels of evidence about therapy is described, with the highest being meta-analyses and large, well-designed randomised controlled trials.(3-5) Lower down the hierarchy are observational studies, a group that includes cohort, case-control and cross-sectional studies. Here we describe the benefits and limitations of observational studies, and how to assess their quality...
September 2016: Drug and Therapeutics Bulletin
journal
journal
21685
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"